Inhibition of αvβ6 promotes acute renal allograft rejection in nonhuman primates

American Journal of Transplantation

Volumn 13, Issue 12, 2013, Pages 3085-3093

  Lo, D J ^a   Farris, A B ^b   Song, M ^a   Leopardi, F ^a   Anderson, D J ^a   Strobert, E A ^a   Ramakrishnan, S ^a   Turgeon, N A ^a   Mehta, A K ^a   Turnbull, B ^c   Maroni, B ^d   Violette, S M ^d   Kirk, A D ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BioBridges LLC   (United States)

^d BIOGEN   (United States)

Author keywords

v 6; Acute rejection; TGF

Indexed keywords

ALPHAVBETA6 INTEGRIN; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; LATENCY ASSOCIATED PEPTIDE; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN 1; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; STX 100; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE FREE SURVIVAL; DRUG EFFICACY; ENZYME INHIBITION; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; NONHUMAN; PRIMATE; PRIORITY JOURNAL; RHESUS MONKEY; STAINING;

ACUTE REJECTION; TGF-Β; ΑVΒ6;

ALLOGRAFTS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; BIOPSY; GRAFT REJECTION; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INTEGRINS; KIDNEY TRANSPLANTATION; MACACA MULATTA; PILOT PROJECTS; RANDOM ALLOCATION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84888381983     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12467     Document Type: Article

References (35)

1. Meier-Kriesche HU, Schold JD, Kaplan B., Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies ? Am J Transplant 2004; 4: 1289-1295.
2. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR., The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333.
3. Li C, Yang CW., The pathogenesis and treatment of chronic allograft nephropathy. Nat Rev Nephrol 2009; 5: 513-519.
4. Hirschberg R., Wound healing in the kidney: Complex interactions in renal interstitial fibrogenesis. J Am Soc Nephrol 2005; 16: 9-11.
5. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA., Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006; 24: 99-146.
6. Blobe GC, Schiemann WP, Lodish HF., Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342: 1350-1358.
7. Lopez-Hernandez FJ, Lopez-Novoa JM., Role of TGF-beta in chronic kidney disease: An integration of tubular, glomerular and vascular effects. Cell Tissue Res 2012; 347: 141-154.
8. Margadant C, Sonnenberg A., Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing. EMBO Rep 2010; 11: 97-105.
9. Akool el-S, Doller A, Babelova A, et al. Molecular mechanisms of TGF beta receptor-triggered signaling cascades rapidly induced by the calcineurin inhibitors cyclosporin A and FK506. J Immunol 2008; 181: 2831-2845.
10. Mantel PY, Schmidt-Weber CB., Transforming growth factor-beta: Recent advances on its role in immune tolerance. Methods Mol Biol 2011; 677: 303-338.
11. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992; 359: 693-699.
12. Marie JC, Liggitt D, Rudensky AY., Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-beta receptor. Immunity 2006; 25: 441-454.
13. Gorelik L, Flavell RA., Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 2000; 12: 171-181.
14. Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients 2010 data report. Am J Transplant 2012; 12 (Suppl 1): 1-156.
15. Annes JP, Munger JS, Rifkin DB., Making sense of latent TGFbeta activation. J Cell Sci 2003; 116 (Pt 2): 217-224.
16. Hyytiainen M, Penttinen C, Keski-Oja J., Latent TGF-beta binding proteins: Extracellular matrix association and roles in TGF-beta activation. Crit Rev Clin Lab Sci 2004; 41: 233-264.
17. Miyazono K, Olofsson A, Colosetti P, Heldin CH., A role of the latent TGF-beta 1-binding protein in the assembly and secretion of TGF-beta 1. EMBO J 1991; 10: 1091-1101.
18. Munger JS, Huang X, Kawakatsu H, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: A mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999; 96: 319-328.
19. Annes JP, Chen Y, Munger JS, Rifkin DB., Integrin alphaVbeta6-mediated activation of latent TGF-beta requires the latent TGF-beta binding protein-1. J Cell Biol 2004; 165: 723-734.
20. Wipff PJ, Hinz B., Integrins and the activation of latent transforming growth factor beta1-An intimate relationship. Eur J Cell Biol 2008; 87: 601-615.
21. Trevillian P, Paul H, Millar E, Hibberd A, Agrez MV., alpha(v)beta(6) Integrin expression in diseased and transplanted kidneys. Kidney Int 2004; 66: 1423-1433.
22. Hahm K, Lukashev ME, Luo Y, et al. Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse. Am J Pathol 2007; 170: 110-125.
23. Puthawala K, Hadjiangelis N, Jacoby SC, et al. Inhibition of integrin alpha(v)beta6, an activator of latent transforming growth factor-beta, prevents radiation-induced lung fibrosis. Am J Respir Crit Care Med 2008; 177: 82-90.
24. Weinreb PH, Simon KJ, Rayhorn P, et al. Function-blocking integrin alphavbeta6 monoclonal antibodies: Distinct ligand-mimetic and nonligand-mimetic classes. J Biol Chem 2004; 279: 17875-17887.
25. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997; 94: 8789-8794.
26. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
27. Weaver TA, Charafeddine AH, Agarwal A, et al. Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nat Med 2009; 15: 746-749.
28. Van Aarsen LA, Leone DR, Ho S, et al. Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism. Cancer Res 2008; 68: 561-570.
29. Detre S, Saclani Jotti G, Dowsett M., A "quickscore" method for immunohistochemical semiquantitation: Validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995; 48: 876-878.
30. Khanna AK, Plummer MS, Hilton G, Pieper GM, Ledbetter S., Anti-transforming growth factor antibody at low but not high doses limits cyclosporine-mediated nephrotoxicity without altering rat cardiac allograft survival: Potential of therapeutic applications. Circulation 2004; 110: 3822-3829.
31. Regateiro FS, Howie D, Cobbold SP, Waldmann H., TGF-beta in transplantation tolerance. Curr Opin Immunol 2011; 23: 660-669.
32. Csencsits K, Wood SC, Lu G, Bishop DK., Transforming growth factor-beta1 gene transfer is associated with the development of regulatory cells. Am J Transplant 2005; 5: 2378-2384.
33. Daley SR, Ma J, Adams E, Cobbold SP, Waldmann H., A key role for TGF-beta signaling to T cells in the long-term acceptance of allografts. J Immunol 2007; 179: 3648-3654.
34. Chen ML, Yan BS, Bando Y, Kuchroo VK, Weiner HL., Latency-associated peptide identifies a novel CD4+CD25+ regulatory T cell subset with TGFbeta-mediated function and enhanced suppression of experimental autoimmune encephalomyelitis. J Immunol 2008; 180: 7327-7337.
35. Shin GT, Khanna A, Sharma VK, et al. In vivo hyperexpression of transforming growth factor-beta 1 in humans: Stimulation by cyclosporine. Transplant Proc 1997; 29: 284.